Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899444 | 0.86 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL22909433 | 0.82 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL29899431 | 0.79 | F2 (0.42) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL4175368 | 0.76 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL24457960 | 0.75 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29899452 | 0.75 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29899453 | 0.75 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29899458 | 0.75 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL22909259 | 0.75 | CA1 (0.31) | CA1CA2CA9CA12CA7 | |
| SCHEMBL29671297 | 0.75 | CA1 (0.31) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | CA1 2665/4885CA2 2232/4885MMP1 4086/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | CA1 4526/4885CA2 4102/4885MMP1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.